Evidence map›Paper›PMID 18395906›Full record

ArticleWorld journal of gastroenterology2008

p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer.

Mohammad Reza Abbaszadegan, Omeed Moaven, Hamid Reza Sima, Kamran Ghafarzadegan, Azadeh A'rabi, Mohammad Naser Forghani, Hamid-Reza Raziee, Ali Mashhadinejad, Mostafa Jafarzadeh, Ehsan Esmaili-Shandiz and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Methylation as a critical epigenetic process during tumor progressions among Iranian population: an overview.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2021
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. The value of serum RASSF10 hypermethylation as a diagnostic and prognostic tool for gastric cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Mohammad Reza AbbaszadeganDivision of Human Genetics, Immunology Reserach Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad 9196773117, Iran. abbaszadeganmr@mums.ac.ir
Omeed Moaven
Hamid Reza Sima
Kamran Ghafarzadegan
Azadeh A'rabi
Mohammad Naser Forghani
Hamid-Reza Raziee
Ali Mashhadinejad
Mostafa Jafarzadeh
Ehsan Esmaili-Shandiz
Ezzat Dadkhah
Mashhad University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo determine p16 promoter hypermethylation in gastric tumoral tissue and serum samples, its impact on p16-protein expression, and correlation with clinical and histological features.

methodsSamples were obtained from 52 histologically confirmed cases of gastric adenocarcinoma. Gastric tissue and serum of 50 age- and sex-matched individuals with normal gastroscopy and biopsy were obtained as control samples. Methylation-specific polymerase chain reaction (MSP) was used to evaluate methylation status of p16 promoter. p16-protein expression was analyzed by immunohistochemical staining on paraffin-embedded sections.

resultsMethylation was detected in 44.2% (23/52) of tumoral tissues. 60.9% of them were also methylated in serum, i.e., 26.9% of all patients (14/52). Methylation was not detected in tissue and sera of control samples. p16-protein expression was decreased in 61.5% of cases (32/52), and was significantly associated with promoter hypermethylation (P < 0.001). Methylation was significantly more frequent in higher pathological grades (P < 0.05). Methylation was not associated with other clinicopathological features and environmental factors including H pylori infection and smoking.

conclusionp16 promoter hypermethylation is an important event in gastric carcinogenesis. It is the principle mechanism of p16 gene silencing. It is related to malignant tumor behavior. Detection of DNA methylation in serum may be a biomarker for early detection of gastric cancer.

Indexed as

Biomarkers, TumorDNA MethylationPromoter Regions, GeneticAgedCyclin-Dependent Kinase Inhibitor p16FemaleHelicobacter pyloriHumansImmunohistochemistryMaleMiddle AgedModels, BiologicalNeoplasm ProteinsPolymerase Chain ReactionStomach NeoplasmsSulfitesBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16hydrogen sulfiteNeoplasm ProteinsSulfites

Identifiers

PMID18395906
PMCPMC2701527
OpenAlexW1547280020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.